Literature DB >> 1837502

Marked variation in blood beta-hexosaminidase in Gaucher disease.

M R Natowicz1, E M Prence, A Cajolet.   

Abstract

Gaucher disease is due to a primary deficiency of acid beta-glucosidase activity and is associated with secondary elevations of several plasma/serum lysosomal enzyme activities, including beta-hexosaminidase. We analyzed plasma and serum beta-hexosaminidase A & B activities in 55 patients with enzyme-documented Gaucher disease. The mean beta-hexosaminidase activity was increased and the percent of the A isozyme decreased, consistent with earlier studies. Gaucher disease patients had 2,067 +/- 1,491 nmol ml-1 h-1 units of beta-hexosaminidase activity with 51.9 +/- 15.5% beta-hexosaminidase A compared to 1,086 +/- 260 nmol ml-1 h-1 and 67.8 +/- 4.0% beta-hexosaminidase A in normal controls and 965 +/- 261 nmol ml-1 h-1 and 43.6 +/- 5.5% beta-hexosaminidase A in Tay-Sachs disease heterozygotes. Contrary to previous reports, marked heterogeneity of both total plasma/serum enzyme activity and isozyme pattern was noted, as some patients had normal enzyme levels and others had severe reductions in the percent of hexosaminidase A. These data argue against the suggestions of recent studies that routine serum beta-hexosaminidase testing done in Tay-Sachs disease heterozygote detection programs can be effectively used to screen for patients with Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837502     DOI: 10.1016/0009-8981(91)90152-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Unusual biochemical presentation of GM1 gangliosidosis: markedly elevated levels of multiple plasma lysosomal enzyme activities.

Authors:  E M Prence; M R Natowicz
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

2.  Heterozygosity for Tay-Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain.

Authors:  M van Bael; M R Natowicz; J Tomczak; E E Grebner; E M Prence
Journal:  J Med Genet       Date:  1996-10       Impact factor: 6.318

3.  Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

Authors:  Lucilla Parnetti; Davide Chiasserini; Emanuele Persichetti; Paolo Eusebi; Shiji Varghese; Mohammad M Qureshi; Andrea Dardis; Marta Deganuto; Claudia De Carlo; Anna Castrioto; Chiara Balducci; Silvia Paciotti; Nicola Tambasco; Bruno Bembi; Laura Bonanni; Marco Onofrj; Aroldo Rossi; Tommaso Beccari; Omar El-Agnaf; Paolo Calabresi
Journal:  Mov Disord       Date:  2014-01-16       Impact factor: 10.338

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.